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Abstract Scientific disciplines such as medicinal- and
environmental chemistry, pharmacology, and toxicology
deal with the questions related to the effects small organic
compounds exhort on biological targets and the com-
pounds’ physicochemical properties responsible for these
effects. A common strategy in this endeavor is to establish
structure–activity relationships (SARs). The aim of this
work was to illustrate benefits of performing a statistical
molecular design (SMD) and proper statistical analysis of
the molecules’ properties before SAR and quantitative
structure–activity relationship (QSAR) analysis. Our SMD
followed by synthesis yielded a set of inhibitors of the
enzyme acetylcholinesterase (AChE) that had very few
inherent dependencies between the substructures in the
molecules. If such dependencies exist, they cause severe
errors in SAR interpretation and predictions by QSAR-
models, and leave a set of molecules less suitable for future
decision-making. In our study, SAR- and QSAR models
could show which molecular sub-structures and physico-
chemical features that were advantageous for the AChE
inhibition. Finally, the QSAR model was used for the
prediction of the inhibition of AChE by an external pre-
diction set of molecules. The accuracy of these predictions
was asserted by statistical significance tests and by com-
parisons to simple but relevant reference models.
Keywords Acetylcholinesterase  AChE  Quantitative
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Introduction
Many scientific disciplines including medicinal- and envi-
ronmental chemistry, pharmacology, and toxicology
address questions related to the effects of small organic
compounds on biological targets, and the relation between
the molecules’ physicochemical properties and the
observed response. To investigate the chemical structural
reasons behind a specific effect and to predict what
chemical features an even more (or less) potent compound
should have, it is crucial to define a structure–activity
relationship (SAR). A SAR establishes a link between the
molecular chemical features and a particular measured
effect. In this paper, we focus on the importance of careful
considerations of the molecules that are used for SAR and
quantitative structure–activity relationship (QSAR) studies.
The molecules used to establish a QSAR dictate the quality
and usefulness of the model, as it is the properties of the
molecules that lead to the biological effect we want to
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model. A prerequisite for (Q)SAR modelling is that the set
of included molecules show substantial and statistically
significant differences in the measured (biological) effect.
The chance of differences in response likely increases if the
molecules’ structures are sufficiently diverse—although the
statistical significance is dependent on the underlying SAR
and the experimental errors of the effect measurements.
Furthermore, the chemical features of investigated mole-
cules need to be varied in such a way that their effects can
be resolved in the subsequent SAR/QSAR studies. There-
fore, we recommend careful selections and investigations
of the sets of molecules used for SAR/QSAR in order to
improve the usefulness of generated models. Here, we have
designed and synthesized a set of inhibitors of the enzyme
acetylcholinesterase (AChE) to illustrate the benefits of
performing a statistical molecular design (SMD) [1] to
create a solid molecular base for SAR and QSAR investi-
gations. We also show the benefits of a careful analysis of
the molecules’ properties before modeling, and the
assessments of the resulting QSAR in relation to simpler
models, here called reference models.
In medicinal chemistry projects, chemists commonly
have to select compounds to synthesize, typically less than
100, from a substantially larger theoretical pool of poten-
tially interesting molecules. These selected molecules may
be designed and synthesized on a linear time scale (one by
one) based on medicinal chemistry experience, which may
lead to improved compounds in some cases, but this is not
a suitable strategy if the objective is to construct a SAR/
QSAR. In such cases, the preferred approach is to design
and select sets of molecules that later can be used to
investigate the biological effects. In SMD, subsets of
molecules are designed based on the principles of design of
experiments (DoEs) [2] where chemical features hypothe-
sized to be important for biological effect are varied in a
systematic way. SMD offers a way to select subsets of
molecules in a sound way from a synthetic- and mathe-
matical point of view, thus aiding chemists to make
‘‘smart’’ subset selections. Selecting compounds based on,
for example, D-optimality [3] or by factorial designs [1, 2],
effectively reduces the physicochemical overlap between
the molecules keeping the number to a minimum. Simul-
taneously, the design makes sure that the subset is repre-
sentative of the full set of conceivable molecules, and that
chemical features (‘‘synthons’’ or ‘‘building blocks’’) return
in several molecules to yield a basis for statistically sup-
ported conclusions regarding biological effect. More spe-
cifically, SMD in SAR analysis makes it possible to
investigate non-additive effects of molecule structural or
physicochemical features. By designing the molecules
through simply combining synthons (building blocks) in a
clever way, it can be ensured that structural fragments
systematically reappear several times in different
combinations among the final molecules. This gives a more
robust basis for identifying combination effects and con-
structing regression models (QSAR). This is achieved
because SMD inherently reduces the co-variation of the
investigated chemical features increasing the possibility to
resolve the impact of each investigated property on the
measured biological effect. If two or more chemical fea-
tures covary, their effects will be confounded and it will be
difficult to distinguish what feature that is responsible for
the effect. For example, if all flexible molecules are lipo-
philic, the effect of these two features will be confounded,
and it will not be possible to resolve whether the biological
effect is dependent mainly on flexibility, lipophilicity, or
both. We recommend careful investigations of the corre-
lation patterns of the descriptor-matrices of a set of mole-
cules (i.e., investigation of the covariance of the X-matrix)
aimed for SAR and QSAR studies. Unfortunately, this is
rarely done today even though it is a simple procedure that
can be performed for any data (i.e., also non-designed
data). Neglecting correlations can result in significant
errors in interpretations and wrongful predictions.
There are a large number of techniques for correlating
chemical and biological data and perhaps the most com-
mon ones are linear methods, such as partial least squares
to latent structures (PLS) regression, non-linear regression
methods such as neural networks, and decision trees such
as random forests [4]. Regardless of method, all models
should be properly evaluated for quality and usefulness [5–
7], by assessing the covariance of the descriptor matrix,
quality of the experimental data, model fit, applicability
domain, prediction capability, and interpretation of the
resulting relationship. The Organization for Economic Co-
operation and Development (OECD) has developed prin-
ciples for the creation and validation of QSAR models [8]
that we encourage modelers to follow. This will allow for
an assessment of the quality of the QSAR models, but,
although important and necessary, this will not show if the
obtained model will add value to the scientific community.
We argue that a minimum requirement for publication of a
QSAR method should be that it surpasses the performance
of simpler methods (reference models, sometimes also
called NULL models). These reference models can include
the linear regression of biological activity using single
physicochemical property of the molecules, such as logP or
molecular weight. The usefulness of a more advanced
QSAR model should be questioned if a reference model
surpasses it in terms of fit and prediction quality.
The compounds designed and synthesized in this study
were evaluated for their inhibition of AChE, which is an
enzyme present in the nervous system. The enzyme is
essential because it hydrolyze the transmitter substance
acetylcholine. The active site consists of the entrance site
(peripheral anionic site, PAS) and the catalytic site (CAS).
200 J Comput Aided Mol Des (2015) 29:199–215
123
Non-covalent inhibitors of AChE are currently used in
symptomatic treatment of, for example, Alzheimer’s dis-
ease [9]. Covalent inhibitors of AChE, such as phosphorus-
based nerve agents (e.g., Sarin), are potent toxins that
interfere with the cholinergic signaling. Molecules (anti-
dotes) that cleave the bond between the enzyme and the
nerve agent can, assuming favorable circumstances, reac-
tivate enzyme inhibited by a nerve agent. New AChE
inhibitors are of great interest to the medical community
because many of the current treatments with AChE inhib-
itors cause grave side effects [10], and most antidotes
exhibit a limited blood–brain barrier penetration [9],
together with a narrow spectrum in treatment of the
intoxication caused by different nerve agents.
QSAR investigations of AChE inhibitors for medical
applications started to appear in the late 1990s and among
the first was a study by Hansch and co-workers [11] where
QSAR-equations based on compounds such as tacrine,
carbamates and physostigmine analogues were presented.
Since then, many AChE QSAR studies have been pre-
sented including carbamates [12–14], analogues of tacrine
[15–18], physostigmine [19], donepezil [20–24], 2,5-pipe-
razinedione [25], 4-aryl-4-oxo-N-phenyl-2-aminylbutyr-
amide [26], minaprine [27], amaryllidaceae alkaloids [28],
and miscellaneous compounds [29, 30]. All of these QSAR
studies were based on already existing experimental data of
molecules not designed for modeling; SMD was not used
in any of the studies and no assessments of the descriptor
matrices were presented. Most commonly, previous studies
have resulted in 3D-QSARs [13–16, 19, 21, 23, 25–27, 29].
2D-QSARs presented have usually been based on physi-
cochemical descriptors [17, 22, 24, 28, 30] and/or topology
descriptors [18, 20]. The dominating regression method
used in these studies was multiple linear regression (MLR)
or PLS, but the models were not compared to any reference
models and were seldom evaluated with an external test
set.
In this study, we have performed SMD to design a set of
molecules, included examples of covariance matrix ana-
lysis of training set molecules, and performed test set
evaluations and reference model comparisons to illustrate
the benefits of using these methods in QSAR modeling.
Results and discussion
SMD of AChE inhibitors
The design of molecules investigated in this study started
from compound 1 (Fig. 1), which was discovered in a high
throughput screening (HTS) campaign [31], and have been
investigated previously for inhibition of AChE [32]. A
retrosynthetic analysis of 1 resulted in synthons i, ii and iii
(Fig. 1) suitable to form a SMD based on three sets of
building blocks in positions pI, pII and pIII.
The SMD was performed in two steps. The first step was
a selection of building blocks to include for pI, pII and pIII
(Fig. 2) and they were selected based on a SAR analysis of
substructures present in hits found in the aforementioned
HTS and on commercially available reactants. The aim
with the design was to investigate the inhibition effect
related to the electronic properties (mainly weakly or
strongly electron withdrawing substituents) and bulk of pI,
and the basicity and bulk of pIII, with a conservative
variation of the linker pII. Note that building blocks at
pI were divided into pIa and pIb to increase the physico-
chemically diversity of the designed molecules.
The second step of the SMD was a selection of a subset
of 18 molecules for synthesis (Table 1). From the 144
possible combinations of the structural fragments at posi-
tions pIa, pIb, pII and pIII, the subset was selected to
represent the whole set in a balanced way, i.e., balanced
with respect to repetition and representation of the struc-
tural fragments. This was achieved by applying a D-opti-
mal design [3] on a matrix describing molecules with
simple indicators of absence (0) or presence (1) of struc-
tural fragments (i.e., conditional descriptors) generated for
the 144 molecules (see Online Resource 1 for statistical
details and Online Resource 2 for design matrix). The
D-optimality criterion assured that the selected molecules
reflected the diversity of the 144 candidates. The D-optimal
set had a condition number of 1.84 showing that structural
fragment were varied independent of each other in the
selected set (lower than 3 is preferred [33] ). Importantly,
each structural fragment in Fig. 2 was represented at least
twice in the subset of 18 molecules and was combined in
such way that a subsequent SAR analysis would reveal the
influence of each structural fragment. To elucidate possible
dependencies, a covariance matrix was calculated (Eq. 1,
Fig. 3) on the conditional descriptors. An inspection of the
covariance matrix confirmed that there was no strong co-
variation in the set. A weak correlation was identified
between structural features p-chlorobenzene/trifluoro-
methylbenzene and benzylic carbon, which meant that
molecules with a benzylic group at the same time con-
tained a para-chlorophenyl or trifluoromethyl-phenyl
moiety.
Synthesis of designed compounds
Scheme 1 shows the synthesis of compounds 1–18. Reac-
tion of sulfonyl chlorides 19a–d or acid chlorides 19e–
i with amines 20a–j produced compounds 1–12 and 21–26.
The alkyl halides 21–23 were converted into the
pyridinium salts 13–15 by heating in pyridine, while the
piperazinyl compounds 16–18 were available from
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tert-butyloxycarbonyl (Boc)-protected intermediates 24–26
by protecting group cleavage using 4 M HCl in ethanol. The
complete synthetic procedure is given in Online Resource 1
and compound characterization in Online Resource 3.
AChE inhibition measurements
The training set of 18 compounds was experimentally
evaluated for their ability to inhibit the enzymatic activity
of AChE (Table 1 and Online Resource 1 for experimental
details). The compounds displayed a wide range of activity
spanning between a half-maximum inhibition concentra-
tion (IC50) of 6.6 lM (14) and 4,200 lM (3), with most
compounds inhibiting AChE in the low- to mid-micromo-
lar range. Thus, the measured biological response had a
sufficient activity range for a SAR/QSAR evaluation, well
outside the experimental and acceptable model error.
SAR and QSAR modelling strategies
and considerations
The choice of method to correlate the molecular descriptors
to the biological response fell on PLS [34], which is a
linear regression method that can account for some non-
linearity in the modelling. PLS was selected due to its
simplicity and transparency; it is no ‘‘black box’’ and
allows for interpretation of the relationship between prop-
erties and response. The quality of the resulting PLS
regression models was assessed by Pearson’s correlation
coefficient (here called R2Y) and the root-mean-square
error of estimation (RMSEE, Eq. 3), which tells us how
well our numerical description of the molecules (our
descriptors) could estimate the biological response of the
training set. We analyzed our models for robustness (i.e.,
stability against small changes in the data) using cross
validation. Each molecule was sequentially left out once in
the model building with subsequent prediction of its pIC50
value; the correlation coefficient between the internal
predictions and the experimental values (Q2) of the total
training set was reported (Eq. 2). For a robust model there
should not be large differences (preferable lower that 0.2
[33] ) between R2Y and Q2, although it should be noted
that the Q2 value is highly dependent on the molecules
included in the training set [35, 36] and the number of
excluded molecules in each cross validation round [37].
The PLS regression coefficients were also robustness-tes-
ted by monitoring their variation throughout the cross
validation procedure, which was important since the
regression coefficients were used to established the SAR
and to interpret the QSAR model. We also chose to per-
form a permutation test [38, 39] to make sure that our
model was not a result of chance correlations. In this test,
the order of the response values (pIC50) was scrambled and
new models were created that should perform worse than
the original model (in terms of R2Y and Q2).
The number of PLS-components to use in a model
requires careful considerations. Too many PLS-compo-
nents will lead to over fitting and wrongful conclusions
regarding the models’ predictive capability. As a guideline,
a PLS model including one response variable should not
require more than one PLS-component, provided that the
relationship between the descriptors and response is linear.
In cases with weak non-linearity, PLS will still perform
well but one or maximum two additional PLS-components
may have to be calculated. The evaluation of the predictive
capability of the QSAR model was done by external test
Fig. 1 Retrosynthetic analysis
of 1 resulted in synthons i, ii and
iii
Fig. 2 Chemical structures of
the three sets of building blocks
pI, pII and pIII that were
selected for the (Q)SAR study;
the building blocks correspond
to the synthons in Fig. 1, and
synthon i was further
disconnected to the aromatic
moiety and the sulfonic amide
forming two subsets (pIa and
pIb)
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Table 1 Chemical structures and AChE inhibition of the 18 compounds in the training set evaluated for AChE inhibition
ID Name Structure IC50 (lM) CI
a (lM) pIC50
1 AL011 13.0 11.3–15.0 4.89
2 AL013 445 321–616 3.35
3 AL012 [1,000b – 2.00
4 AL007 69.5 54.6–88.5 4.16
5 AL008 101 82.7–123 4.00
6 AL006 12.8 11.0–15.0 4.89
7 AL015 4,250 1,730–10,500 2.37
8 AL016 12.0 10.2–14.0 4.92
9 AL005 67.7 57.4–79.8 4.17
10 AL014 323 207–504 3.49
11 AL009 2,430 1,240–4,790 2.61
12 AL010 78.0 65.3–93.1 4.11
13 AL017 25.0 21.2–29.6 4.60
14 AL021 6.6 5.6–8.0 5.18
15 AL022 22.2 19.7–24.9 4.65
16 AL018 109 87.2–137 3.96
17 AL020 4,204 165–107,000 2.38
18 AL019 136 118–156 3.87
a Confidence interval (95 %). b Uncertainty in IC50 determination due to poor compound solubility
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sets (i.e., never included in the model building procedure)
and by comparisons with reference models, which is the
described in more detail in the following sections.
Structure–activity relationships of AChE inhibitors
In the SAR analysis, the molecules’ inhibition of AChE
expressed as pIC50 (the Y matrix) was modeled as a
function of the conditional descriptors (absence or presence
of structural fragments) used in the SMD (the X matrix, see
Online Resource 2). The PLS described 79 % of the total
variation in Y (R2Y), had an adjusted R2Y of 0.77, and an
internal prediction capacity of 26 % [cross-validated Q2
(cum), Eq. 2]. The use of a highly reduced subset of 18 out
of 144 molecules, with low redundancy in structural fea-
tures, contributed to the relatively low cross validation
value. In other words, predicting the response for a mole-
cule by using the structural information of the other 17
molecules is particularly challenging here since we have
designed the molecules to be as different as possible. In
fact, it can be showed [35] that the value of Q2 as an
estimator of the internal prediction capacity decreases with
the size of the training set and that Q2 is particularly
underestimated when calculated on designed data [36].
Leave-many-out would be the preferred method for deter-
mining Q2 instead of leave-one-out if it is applied to sets of
Scheme 1 General synthetic scheme detailing synthesis of compounds 1–18
Fig. 3 Covariance matrix of
conditional descriptors of the
selected subset of 18 molecules
showing pairwise correlation of
the descriptors ranging from
minimum (0.00) to maximum
(1.00) correlation; descriptor
names are given on the axis and
colors indicate an increasing
covariance dark blue to light
blue, green, orange, red and
black
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molecules with higher redundancy. The RMSEE was 0.47,
indicating an internal estimation error of a half log-unit.
The PLS regression coefficients (Fig. 4) were analyzed
to identify how the different structural fragments in the
molecules influenced the pIC50. Most influential were
fragments in pIII binding in the CAS of AChE followed by
PAS-binding fragments in pIa, while the effects of
changing linker length (pII), changing between amide and
sulfonamide in pIb, or adding a benzylic CH2 were non-
significant. From the regression coefficient values, it was
clear that N-dimethyl, N-diethyl or especially pyridinium in
pIII, and a benzothiophene or 4-methyl-2-nitrobenzene in
pIa were advantageous for the potency. A morpholine in
pIII was clearly disadvantageous. The benzothiophene and
methyl-nitrobenzene substructures has been found before
in AChE inhibitors [30], although not combined with the
same moieties presented here, while the isoindolinone-
phenyl moiety as a PAS binder is novel. The well-known
fact that cationic molecules bind to the CAS region of
AChE was corroborated here, since the permanent pyridi-
nium cation was the most potent. Notably, common oxime-
based antidotes for nerve agent intoxication contain a
pyridinium moiety [40], for example pralidoxim and HI-6.
No approved drug molecules for Alzheimer’s disease
treatment, and only one myasthenia gravis drug
(pyridostigmine) targeting AChE contain a pyridinium
[41], possibly because of the poor gut absorption and
blood–brain barrier passage associated with (permanent)
cations. The morpholine as a CAS-binding moiety has been
reported before, and is present in the weak AChE inhibitor
minaprine and analogues [42]. Similar to our finding here,
if compared to other substituents such as piperidinyl and
triethylamin, morpholinyl have been shown to be less
potent [42, 43]. Nevertheless, morpholinyl per se cannot be
considered a poor binder of AChE since it is present in
inhibitors in the nM to lM range [30, 44–46].
Descriptor covariance and QSAR analysis
The SAR analysis was extended by calculating quantitative
molecular physicochemical descriptors aiming for QSAR
modeling of the AChE inhibition expressed as pIC50 for the
training set molecules. The training set consisted of 24
molecules, which included the original 18 molecules but
with both cationic and neutral protonation states for mol-
ecules with morpholine or piperazine moieties. Descriptors
were calculated for the whole molecules (global descrip-
tors) as well as for sub-structures of the molecules corre-
sponding to the PAS- and CAS-binding moieties, giving
325 descriptors (Fig. 5, and Online Resource 2). It is
important to stress that, even though the SMD resulted in a
set of molecules with systematically and independently
varied structural fragments, the molecule selection was not
performed in physicochemical descriptor space. Therefore,
it was of particular importance to perform a careful ana-
lysis of the physicochemical descriptor matrix to detect
dependencies before further modeling (Fig. 5). Accord-
ingly, the covariance matrix of all 325 descriptors of the 24
molecules was calculated to identify descriptor correlations
(Eq. 1, and see Online Resource 2). Two descriptors could
correlate for three reasons. (1) The descriptors described
the same molecular property (e.g., molecular weight and
the number of heavy atoms both describe size). (2) The two
descriptors correlated just by chance. The risk of chance
correlation increase with number of pairwise comparisons,
e.g., the risk of chance correlations at a 0.05 significance
level is 1–0.95K for K comparisons. (3) The two descriptors
correlated due to co-variation of two chemical features
within the molecules in the set (e.g., the benzylic fragment
and para-substituted aromatic fragments in this set). All of
this will influence the QSAR modeling in terms of model
quality, including interpretation and prediction capacity.
The analysis of the covariance matrix revealed that the
main part of the descriptors were related to the size and
flexibility of the molecules; 35 % (40 out of 113) of the
global descriptors had a correlation coefficient larger
than 0.7 compared to the surface area or number of rotat-
able bonds. It was clear that the descriptors describing
Fig. 4 The PLS regression coefficient values showing the influence
of the different structural fragments on the inhibition of AChE;
aromatic PAS-binding fragments in pI are shown in black, linker
fragments (in both pI and pII) in dark grey, and basic CAS-binding
fragment in pIII in light grey, and confidence intervals (90 %) were
calculated using jack-knifing [47] on models generated in the cross-
validation procedure
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electronic properties and (partial) charge distributions,
which are of particular interest here, were less redundant
than for example size and lipophilicity. In cases where
descriptors such as indices and binned descriptors corre-
lated with more interpretable physicochemical descriptors,
the latter were selected. We performed a careful selection
(Fig. 5) of a subset of 14 descriptors (Table 2) out of the
325 to be used in the QSAR modeling aiming to keep the
descriptor redundancy low and avoiding chance correla-
tions. Regarding correlations due to co-variation of
chemical features within the molecule set, it is important to
include such descriptors in order to keep track of the
confounding pattern later on in the modeling. We made the
selection to included descriptors with (1) low internal co-
variation as determined from the covariance matrix of all
325 descriptors, and (2) a rational relevance for the
molecular interaction between the inhibitors and AChE
based on previous published results. We emphasize that no
account was taken of the correlation of descriptors to the
inhibition of AChE in the selection procedure; the selection
was solely focused on the X-matrix.
The covariance matrix of the 14 descriptors used for
modeling (Fig. 6) showed, as expected due to the SMD, no
correlations between the CAS and PAS descriptors.
However, within the subset of CAS descriptors it is clear
that the selected structural fragments (building blocks)
resulted in a strong correlation (0.94) between highest
occupied molecular orbital (HOMO) and lowest unoccu-
pied molecular orbital (LUMO), indicators of polarizabil-
ity, making it impossible to resolve these effects. It can also
be seen that it is the structural fragments in CAS that
dictate the lipophilicity of the molecules (i.e., correlation
between CAS_Q_VSA_FPPOS and logP of 0.76) and the
PAS structural fragments that is responsible for the varia-
tions in shape between the molecules (i.e., correlation
between PAS_npr1 and rgyr of 0.78).
The QSAR model contained two PLS-components
described 79 % of the total variation in Y (R2Y(cum)), an
adjusted R2Y(cum) of 0.77, and an internal prediction
capacity of 60 % [Q2(cum), Eq. 2]. The pIC50 values
estimated by the model versus the measured values show a
linear relationship (Fig. 7a) with a RMSEE of 0.46. A
permutation test indicated that the model was not the result
of chance correlations between X and Y (see Online
Resource 1).
The regression coefficient plot (Fig. 7b) of the first PLS-
component (72 % of the variation) revealed that the
strongest inhibitors in the set generally had a higher logP
Fig. 5 QSAR model building approach where descriptors first were filtered (descriptor selection) based on the covariance matrix and knowledge
of important molecular physicochemical properties for AChE inhibition followed by PLS regression to yield the QSAR-model
Table 2 Descriptor name [48] and explanation for descriptors included in the QSAR model
Global CAS PAS
b_1rotR Fraction of rotatable single bonds VSA_FPNEG Fractional negative polar
vdW surface area




Log of the octanol/water partition
coefficient calculated from a linear
atom type model
VSA_FPOS Fractional positive vdW
area
AM1_LUMO Energy (eV) of the lowest
unoccupied molecular
orbital




vdw_area Area of vdW surface (A˚2) AM1_HOMO Energy (eV) of the highest
occupied molecular
orbital
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(logP(o/w)), relatively more rotational bonds (b_1rotR),
and a smaller radius of gyration (rgyr) and were thus more
globular. The CAS-binding moiety of the better inhibitors
generally had smaller and more polar van der Waals (vdW)
areas (CAS_Q_VSA_FPNEG/CAS_Q_VSA_FPPOS), lower
dipole moments (CAS_dipole), and lower energy of the
HOMO and/or LUMO (cannot be resolved due to con-
founding). Furthermore, the stronger inhibitors had an
asymmetric PAS moiety in terms of principal moment of
inertia (PAS_npr1) and lower LUMO energy of the PAS-
binding moiety. The importance of a low LUMO energy of
the PAS binding moiety corroborates previous findings [30,
45] indicating that an aromatic systems with a high
reduction potential may be preferential in PAS. It is a
known fact that a positive charge—manifested here in a
small and more polar vdW area of the CAS-binding moi-
ety—is important for AChE interactions. Cations have
been shown to interact with aromatic side chains in the
CAS region in numerous crystal structures, e.g., PDB code
1ACJ [49]. We included both protonation states of mole-
cules containing piperazinyl and morpholinyl moieties with
the argument that they possibly could be neutral upon
binding, which could influence their inhibition of AChE
(AChE preferably bind cationic ligands). Notably, these
molecules were moderate inhibitors at best and little dif-
ference were seen between charged and neutral states in the
model (Fig. 7a), indicating that their poor inhibitions of
AChE were not related to their protonation states. The
rigorous molecular design and evaluation thereof guaran-
tees that the conclusions drawn here regarding the molec-
ular properties’ influence on compound inhibition of
AChE, are indeed certain, within the applicability domain
of these molecules.
Predictive capability of the QSAR model
Three external test sets (never included in the QSAR model
development) were used to evaluate the QSAR model, and
examples of these molecules are shown in Fig. 8 (see
Online resource 1 for a complete list). Set1 included
molecules 27–31 (5 compounds) that were synthesized as a
prediction set for the original design. 27–29 contained new
combinations of structural feature that were found to be
beneficial in the SAR, e.g., 27 with 4-methyl-2-nitroben-
zene in pI and pyridinium in pIII. 30 and 31 contained ‘‘the
medicinal chemists’ choice’’ of structural features, e.g.,
nitrobenzene in pIa and a thiazole in pIII. Set2 included
molecules 36–42 (7 compounds) that consisted of structural
Fig. 6 The covariance matrix
of descriptors included in the
QSAR model and descriptor
names are given on the axis and
colors indicate an increasing
covariance from dark blue to
light blue, green, orange, red
and black
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fragments not included in the original design, i.e., the same
fragmentation scheme does not apply, leading to more
challenging predictions. Set3 consisted of 43–62 (20
compounds) [32], where only pIa was structurally varied;
pIb, pII and pIII consisted of a 1-(diethylamino)-2-(sulfo-
nylamino)ethane moiety. Hence, only the PAS binding part
has been considered in the predictions for Set3.
The three test sets differed in activity ranges where IC50
was in Set1 between 2.6 and 19 lM, in Set2 between 0.3
and 1.3 lM, and in Set3 between 6.8 and 162 lM with one
uniquely active compound (62) at 0.7 lM. Prediction Set4
combined all compounds from the first three prediction sets
giving 32 compounds and an overall activity range between
0.3 and 162 lM (pIC50 3.79–6.59).
The predicted inhibition capacity of the test set versus
the experimental measurements is presented in Fig. 7c. The
overall root-mean-square error of the predictions [RMSEP,
Eq. 5] for the test sets was 0.57 (Table 3), which is in the
same magnitude as the training set RMSEE of 0.46. The
test sets were different in terms of prediction errors and
distributions of the predicted values (Fig. 7c; Table 3).
Molecules in Set1 that contained new combinations of
Fig. 7 QSAR model based on PLS with a measured versus estimated
values of pIC50 for molecules included in the model, where c and n
indicates cationic and neutral molecules, respectively, b regression
coefficients of descriptors where prefixes CAS and PAS indicates
descriptors calculated for sub-structures binding in the CAS and PAS
of AChE, respectively, and confidence intervals (90 %) were
calculated using jack-knifing [47] on models generated in the cross-
validation procedure, c measured versus predicted pIC50 values,
including the prediction sets Set1 (black squares), Set2 (gray
squares) and Set3 (gray dots) and the training set (black unfilled
circles) for comparison, where c and n indicates a cationic and neutral
molecule, respectively, d applicability domain assessment using the
distance to model in X (DModX, Eq. 4) of the prediction set and
training set molecules, where DCrit 0.05 represents the 95 %
confidence limit of the training set molecules
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structural fragments from the training set were indeed
among the most active molecules in that class. Predictions
to distinguish the activity within the set were, however, not
successful (reflected in the RMSEP value of 0.68) due to
the low resolution of the model, and the low activity span
of one pIC50 unit of Set1. Similar trends could also be seen
for Set2 and Set3. Molecules of Set2 were different in
terms of physicochemical properties (DModX, Fig. 7d) and
were predicted to be substantially stronger inhibitors than
those included in the training set, which was also the case
when testing them experimentally. It was not possible to
rank Set2 molecules within the class (pIC50 between 5.88
and 6.59). The structural changes of the aromatic moiety
binding to PAS in Set3 were predicted to have a moderate
effect on the inhibition capacity and it was not possible to
predict which structural changes that were more or less
beneficial. The exception was 62 that was predicted to be a
substantially better binder that the rest of Set3, and indeed
it was. We concluded that the individual test sets were not
appropriate as test sets due to the small activity span and/or
low chemical diversity, rather, all three were needed to
validate the model. Together the three sets possessed an
activity span of two pIC50 units, which is similar to the
training set, but with a (desired) shift in activity from pIC50
of 2.37–5.18 (the training set) to pIC50 of 3.79–6.58 for the
test set.
QSAR model predictions in comparison to simple
reference models
To evaluate the quality and usefulness of the QSAR model
further, it was compared to seven simple reference models
also based on the training set molecules. Three non-
regression based methods were used to predict the response
values of the molecules in the test set, the average and
median of the experimental pIC50 values of the training set,
and a nearest neighbor estimation, based on the assumption
that similar molecules have similar biological activity. For
each molecule in the test set, we let experienced synthetic-
and medicinal chemists at the department, not previously
involved in the project, perform unprejudiced selection of
the most similar molecule in the training set (without
knowing any response values). In addition, we calculated
four linear regressions using each of the descriptors logP,
TPSA, and vdW area, and a PLS model based on the three
descriptors (Table 3). For the regression-based reference
model predictions, the training set pIC50-values showed a
weak correlation with logP (R2 of 0.38) but no correlation
with TSPA, or vdW area (see Online Resource 1). The
reference model ‘‘PLS’’ based on the descriptors logP,
TPSA and vdW area as X and the pIC50 as Y, gave a two-
component PLS model with R2Y(cum) of 0.46 (adjusted
R2Y(cum) of 0.41) and a cross-validated Q2 of 0.32 (cf. the
QSAR model statistics of 0.79, 0.77, and 0.60,
respectively).
The pIC50-values of molecules in the external test sets
Set1–4 were predicted using the seven reference-models
and the prediction errors from all models are presented in
Table 3. The reference models’ prediction accuracy was
inferior compared to the QSAR model. Generally, median,
average, logP, TPSA and vdW area were poor predictors of
pIC50, while the PLS and nearest neighbor reference model
performed slightly better.
Analyzing individual reference-model prediction errors
for each of the different test sets revealed that the nearest
neighbor predictions performed well for Set1. This was not
surprising, since Set1 was selected to extract the best
compound features out of the training set, a selection
performed by chemists (although not the same chemists
that created the reference model). Median and nearest
neighbor values seem to be a reasonable pIC50 predictor for
Set3; the linear regression based on logP gave reasonable
predictions for Set2, while the PLS model performed
Fig. 8 Representative
molecules of prediction sets
Set1 (27), Set2 (36), and Set3
(60)
Table 3 QSAR- and reference model statistics including goodness-
of-fit and RMSEP (Eq. 5)
Model R2 RMSEP
Set1 Set2 Set3 Set4
QSAR 0.77a 0.68 0.67 0.50 0.57
Average –b 1.52 2.44 0.95 1.49
Median –b 1.23 2.14 0.70 1.25
Nearest neighbor –c 0.44 2.10 0.69 1.13
logP 0.38 1.32 0.88 1.03 1.05
TPSA 0.01 1.63 2.35 0.95 1.48
vdW area 0.03 1.33 2.60 0.93 1.51
PLS 0.41a 0.93 0.73 1.14 1.03
a R2Y adjusted. b Not relevant since the variance of the average and
median y is zero. c Not relevant because this reference model only
concerns the test sets
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relatively well for Set1 and Set2. None of the reference
models was comparable to the QSAR model in prediction
capacity of the total set of all test set molecules (Set4).
So far, we have investigated and compared the predic-
tion error of the QSAR and reference models, now we
analyze if the predicted pIC50 values resulting from the
models were significantly different from the measured
pIC50-values. We assume that the predicted and measured
values are equal (the null hypothesis) and tested whether
this holds (with a 95 % confidence limit) or should be
overruled by the alternative hypothesis (that they differ).
This was tested using a parametric F test for equal variance
and a paired student t test for equal mean (in case of nor-
mally distributed data (according to Anderson–Darling
(AD) test, [50]) and non-parametric tests (Kolmogorov–
Smirnov (KS) [51, 52] and Mann–Whitney (MW) U test
[53, 54] ), which are less sensitive to non-normal distri-
butions within samples. The tests showed satisfactory
results; the QSAR models’ predictions are equal to the
measured (they are drawn from the same distribution with a
probability p [ 0.05), that is, the prediction values of the
inhibition capacity of molecules in the different test sets
were not different from the experimental values (Table 4).
The test results of the reference models further strengthen
the usefulness of the QSAR model; the predictions of the
test sets by the reference models gave values that are not
significantly equal (p \ 0.05) to the experimental data as
the null hypothesis was rejected for most reference models
(except for the nearest neighbor predictions of Set3;
Table 4). Not all models and prediction sets could be tested
by all statistical tests, since there are different criteria that
need to be fulfilled (see the Experimental Section and
Online Resource 1).
For the individual test sets, one or more reference
models were significantly different from the measured
pIC50-values. Importantly, the evaluation was dependent
on the size and the composition of the prediction sets, the
smaller they were the greater the uncertainty, represented
with a higher F- or t critical value. Set1 included molecules
structurally similar to the training set molecules but the
prediction errors were as high for this set as for the more
dissimilar Set2, which may be somewhat surprising. Nev-
ertheless, the statistics showed that the predictions for Set2
was more uncertain, illustrated by higher F- and t-values
compared to Set1. The nearest neighbor models predictions
of Set3 pIC50 was statistically equal to the measured
although this model was not successful in predicting all test
set molecules (Set4). The statistical tests in Table 4 and the
Table 4 Statistics test presenting p values including, t test, Kolmogorov–Smirnov and Mann–Whitney, comparing the predicted pIC50 values
from the QSAR or reference models to the measured pIC50 values
Test/Model Set1 Set2 Set3 Set4
t testa t testa t testa KSd t testa KSd MWe
QSAR 0.163 0.073 –b 0.275 –c 0.518 0.330
Nearest neighbor –c –c –c 0.275 –c 0.007 0.013
LogP 0.000 0.005 0.000 0.000 –c 0.000 0.000
vdw –b –b –c 0.000 –c 0.000 0.000
TPSA –c –c –c 0.000 –c 0.000 0.000
PLS 0.003 0.030 –c 0.000 –c 0.000 0.000
a Paired (two-tailed) students t test where p \ 0.05 rejects null. b Did not pass the one-tailed F test where calc. [crit. rejects null. c Non-
normally distributed data was not used in F/t tests. d Kolmogorov–Smirnov test where p \ 0.05 rejects null. e Mann–Whitney test where
p \ 0.05 rejects null
Table 5 The molecular struc-
tures for which descriptors were
calculated
pIa ? pIb (PAS) pIII (CAS)
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prediction errors in Table 3 confirmed that predictions by
the investigated reference models were significantly less
successful than the QSAR model (see Online Resource 1
for F and t test details).
Conclusions
A strategy for the design and assessments of sets of mol-
ecules and evaluation of SAR and QSAR models has been
presented that showed the benefits of thinking ahead and
using SMD and co-variation analysis when planning a
SAR/QSAR investigation. A set of inhibitors of the
enzyme AChE was designed using SMD that yielded
molecules with diverse structures but with repeating
structural fragments. This is very important in order to
avoid confounding in the measured effects, which would
lead to wrongful conclusions in subsequent SAR and
QSAR modeling. Co-variation patterns were analyzed
through covariance matrices simply calculated from a
conditional descriptors matrix. The designed compounds
were shown to inhibit AChE and had a reliable potency
spanning from molar to micromolar, with the majority of
compounds having an IC50 in the low micro-molar range.
A PLS-model based on conditional descriptors resulted
in a clear and transparent SAR analysis, which could reveal
molecule sub-structures that were advantageous for the
AChE inhibition. The permanent cation pyridinium, and a
benzothiophenyl or 4-methyl-2-nitrophenyl was most
advantageous in CAS and PAS, respectively, and a mor-
pholinyl in CAS was detrimental to binding. A QSAR
model was calculated based on physicochemical descrip-
tors carefully selected to include molecular properties
known to be important in inhibitor-AChE binding and to
avoid descriptor correlations. The model showed good
statistics in terms of model fit, cross-validation and no
chance correlations. The QSAR model was used to satis-
factory predict the pIC50 of molecules in three prediction
sets. Combinations of the most advantageous sub-struc-
tures identified in the SAR-model, i.e., 4-methyl-2-nitro-
phenyl and pyridinium, gave a molecule with higher pIC50
than any in the training set. The importance of the test set
was highlighted by using sets with different activity spans.
A set of simple albeit relevant models, reference models,
were calculated and these models were proved statistically
to be inferior to the QSAR model in terms of training- and
test set pIC50 predictions.
Much effort has been made to encourage the SAR and
QSAR community to adopt some simple benchmarks to
improve the quality of models. We believe that the strategy
presented here of compound design and evaluation, serves
to illustrate the value of SMD, covariance analysis and
statistical tests in molecular design and QSAR modeling,
and hope that this will inspire to improve QSAR modelling.
Experimental section
Statistical molecular design and covariance matrices
D-optimality and covariance matrices based on conditional
descriptors from the SMD were calculated from a binary
matrix where molecules were described by the presence (1)
or absence (0) of a certain structural feature (see Online
Resource 2 for matrix). All combinations of the molecular
fragments in Fig. 2 resulted in a set of 144 possible mole-
cules, i.e., all possible combinations of all fragments in their
respective position pIa, pIb, pII and pIII. A subset was
selected out of the 144 using D-optimal design [3]. In
D-optimal design, selections are made from X (here, the total
set of 144 possible molecules with their conditional
descriptors) so that the determinant of the matrix Xsel’Xsel is
maximized (Xsel is the selected set with their conditional
descriptors). By maximizing the determinant of the selec-
tions, it is assured that the diversity in the designed set is
reflecting the diversity of the total set. The selected D-opti-
mal set was evaluated by condition number values of Xsel to
investigate whether the structural features were varied
independent of each other (where a completely orthogonal
design have a value of 1). All descriptors were centered and
scaled to unit variance prior to D-optimality calculations and
covariance matrix calculation in Matlab [55].
Molecular descriptor calculation
The molecules’ structures were curated in terms of tauto-
meric forms and protonation states (MarwinView pka cal-
culations) [56] in assay conditions pH 8 (Table 5). Note
that the some amines in pIII may be neutral or cationic and
both forms were included for ambiguous molecules com-
prising morpholine (3, 7, and 11) and piperazine (16, 17,
and 18) The calculations showed that morpholinyl and
piperazinyl would be 40 and 2.5 % neutral, respectively, at
pH 8. 3D-conformations of the molecules were generated
by OMEGA [57, 58] with the MMFF94 s force field [59].
The values for OMEGA parameters rms and ewindow was
set to 0.5 and 40, respectively, and all generated confor-
mations were collected. ROCS [60, 61] was thereafter used
to overlay the conformations against an X-ray crystal
structure of 36 (AL137) in complex with AChE [31] since
the ligands are assumed to bind in an outstretched con-
formation. The conformation with the highest Tanimoto-
Combo score value was selected and used in calculations of
2D and i3D descriptors in MOE [48]. Descriptors were
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calculated for the entire molecule (global) as well as the
CAS and PAS binding part, pIa ? pIb and pIII, respec-
tively (Table 5).
Covariance matrix calculations
Covariance matrices on descriptors (centered and scaled to
unit variance) was constructed by the calculation of cor-








where x1 and x2 are values for descriptors 1 and 2 for
molecule i, and N is the number of molecules. Correlation
coefficients are reported as absolute values and calculations
were done in Matlab [55]. The matrices including condi-
tional- and quantitative descriptors are presented in Online
Resource 2.
Partial least-squares regression
PLS regression [34, 62] was used to correlate the training
set descriptor data matrix X to the inhibition of AChE
(matrix Y) using the SIMCA software [63]. The inhibition
was expressed as the pIC50, which is the -log of IC50 in
molar (M) concentration. All descriptors and the response
were centered and scaled to unit variance before model
building. The quality of the PLS models were determined
from the Pearson’s correlation coefficient R2Y (derived
from the regression between X and Y, not to be confused
with R2X which describes the variation in X used in the
regression), the adjusted R2Y (sum-of-squares adjusted for
the number of degrees of freedom), and the Q2 (derived
from cross-validation) according to
Q2 ¼ 1:0  PRESS=SS ð2Þ
where PRESS is the prediction error sum of squares, SS is
the sum of squares. Cross validation was performed by the
leave-one-out method. The internal prediction error, i.e.,
measured y versus the fitted y or the root-mean-square error
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where N is the number of molecules (i) and A is the number
of PLS-components. The descriptors of the test set mole-
cules were compared to training sets’ to assess the appli-
cability domain by using the normalized distance to model
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where N is the number of molecules (i), K is the number of
descriptors, eik are the X-residuals of molecule i for
descriptor k, A is the number of PLS-components, and v is a
correction factor with a value slightly higher than 1 com-
pensating for the fact that DModX would be slightly
smaller for an observation that is part of the model. Pre-
dicted molecules significantly dissimilar from the model
molecules were identified using normalized DModXPS,
which is the same as DModX but without the correction
factor v. The prediction error of external test molecules i.e.,
measured y versus the predicted y, or the root-mean error of
prediction (RMSEP) was calculated according to
RMSEP ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPN





where N is the number of molecules (i). Model validity and
chance-correlations between X and Y were quantified with
permutation experiments in SIMCA [63] where the order of
pIC50-values in Y was scrambled 200 times and new PLS-
models were created and compared to the original model
[38, 39]. Two kinds of regression models were derived by
PLS calculations between the pIC50 and (1) the conditional
descriptor set and (2) the quantitative descriptors describ-
ing the 24 molecules, in the training set. Confidence
intervals (90 % confidence limit) for regression coefficients
were calculated using jack-knifing [47] on the multiple set
of models resulting from the cross validation procedure.
The coefficients (centered and scaled to unite variance)
were used to interpret the relative importance of the
descriptors and the underlying chemical property. A large
positive coefficient for a structural feature or descriptor
indicated that that feature/descriptor was positively corre-
lated with the pIC50. Conversely, a negative coefficient
indicated that a feature/descriptor was negatively corre-
lated to pIC50.
Compound sets for pIC50 predictions
Three test sets of molecules were used for pIC50 predic-
tions in the QSAR model. Note that none of these mole-
cules had been part of the QSAR model building. Set1
included five molecules 27–31. Set2 included seven ana-
logues 36–42 to the molecule C7653, another hit from the
HTS [31], and these compounds were synthesized and
biologically evaluated here. Set3 included 20 molecules
43–62 that were close analogous to molecule 1 discovered
in a HTS [31] and these molecules are reported to be AChE
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inhibitors [32]. Set4 included all molecules from Set1–3.
Prediction set molecule structures, synthesis-, and biolog-
ical data are presented in Online Resource 1.
Reference model building
Seven simple reference models were calculated for the
evaluation and comparison to the prediction power of the
QSAR model. Two of the reference models were based on
the average or the median of the pIC50 values for the mole-
cules in the training set. These averages and medians were
assumed predicted values of pIC50 for all 24 molecules, and
were compared to the measured pIC50 in RMSEP calcula-
tions according to Eq. (5). Three reference models were
linear regressions based on one descriptor—logP, TPSA, or
vdW area—and the pIC50 values. Predicted pIC50 values
from the regression were calculated from the straight-line
equations for each individual regression model (see Online
Resource 1 for plots and equations), and the RMSEP value
from Eq. (5). A PLS-regression model was calculated con-
taining three descriptors logP, TPSA and vdW area and the
predicted pIC50 values from this model were compared to the
measured according to Eq. (5). Finally, we let six experi-
enced synthetic/medicinal chemists note for each molecule
in the test sets which molecule in the training set they found it
most similar to (see Online Resource 1). By consensus, each
molecule in the test set was predicted to have the activity of
the most similar molecule in the test set. These predictions
were called the ‘‘nearest neighbor’’ model.
Statistical tests of predicted pIC50 values
QSAR model and reference models predicted pIC50 for test
Sets 1–4 were tested for the probability that they were
drawn from a normal distribution using the AD test [50], at
a confidence limit of 95 % (p = 0.05), implemented in
Excel [64, 65]. Alternatives to F and t test when facing
non-normal data are non-parametric tests such as the KS
[51, 52] and MW U test [53, 54] when the aim is to
compare the sample distributions of two sets of data. The
number of data points in each set needed to exceed ten and
seven in KS and MW, respectively. More details are given
in Online Resource 1.
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